Immunomic Therapeutics
US-based Immunomic Therapeutics, Inc. develops vaccines for allergies and other health targets.
Founded
2005US-based Immunomic Therapeutics, Inc. develops vaccines for allergies and other health targets.
Founded in Rockville, United States, Immunomic Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to pioneering the development of vaccines using lysosomal associated membrane protein (LAMP) technology. The company's core mission is to create innovative vaccines for the treatment of allergies and other significant health targets. Their product pipeline includes ITI-1000 and ITI-1001 for Glioblastoma Multiforme and ITI-3000 for Merkel Cell Carcinoma, focusing on addressing critical unmet medical needs.
Immunomic Therapeutics has attracted notable investors and partnerships, contributing to its growth and development. The company has achieved significant milestones in advancing its clinical trials, particularly in the field of oncology. Its innovative approach has the potential to revolutionize vaccine development and impact patient outcomes positively. The overall impact of Immunomic Therapeutics is marked by its commitment to transforming the landscape of immunotherapy and providing new hope for patients with challenging health conditions.
Companies similar to Immunomic Therapeutics include AIM Immunotech, Immunome, MimiVax and Agilvax.
Immunomic Therapeutics was founded in 2005.
Immunomic Therapeutics' headquarters is located in Rockville, MD, US.
Immunomic Therapeutics' most recent funding round was for $61.3M (USD) in April 2020.
As of Apr 23, 2020, Immunomic Therapeutics has disclosed funding of $75.4M (USD). Undisclosed round amounts are excluded.
Immunomic Therapeutics has 31 employees as of Feb 5, 2024.
agilvax.com
